Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2024.09.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Xinyuan Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Myocardial Reperfusion Injury, Cardiotonic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
BACKGROUND: Myocardial ischemia-reperfusion (MI/R) injury tends to affect cardiac function and leads to poor patient prognosis, and there is still no effectively targeted drug to develop anti-von Willebrand factor (VWF) aptamer in acute coronary heart disease. However, the newly anti-VWF aptamer BT200 is applied not only for stroke and hemophilia but also for antithrombolism function in clinical development. The role of BT200 in acute myocardial injury during MI/R is still unknown. OBJECTIVES: To investigate the cardioprotective effect of aptamer BT200 in a mouse model of MI/R. METHODS: C57BL/6 mice were subjected to 30-minute ischemia and 24-hour reperfusion to establish MI/R model. Mice were treated with intravenous injection of cy3-labeled BT200 and were observed by an in vivo imaging system at different time points. Then, mice were sampled and evaluated by echocardiography, Evans triphenyltetrazolium chloride staining, histopathologic, western blotting, and real-time quantitative polymerase chain reaction assays to detect cardiac injury and inflammation response after 24-hour reperfusion. RESULTS: BT200 aptamer can enter and infiltrate into the ischemic myocardium after 24-hour reperfusion. BT200 was shown to inhibit VWF A1 activity and prolong bleeding time in MI/R mice. Moreover, BT200-treated mice had a significant reduction in infarct size and an improvement in cardiac function post-MI/R. BT200 treatment can also alleviate MI/R-induced microvascular obstruction, inflammation response, and cardiomyocyte apoptosis. CONCLUSION: Pharmacologic targeting of VWF with BT200 alleviates acute MI/R injury in a murine model and may be a novel therapy strategy for acute myocardial infarction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Cardiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: xyqah@163.com.
- Department of Cardiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: pujun310@hotmail.com.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Chen, X., Liao, X., Lu, G., Ma, Y., Wang, R., Yuan, A., Xie, Y., & Pu, J. (2025). Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.09.032
Vancouver
Chen X, Liao X, Lu G, Ma Y, Wang R, Yuan A, et al. Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.09.032
BibTeX
@article{Chen2025,
author = {Chen, Xinyuan and Liao, Xianying and Lu, Guiping and Ma, Yue and Wang, Ruowen and Yuan, Ancai and Xie, Yuquan and Pu, Jun},
title = {Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2024.09.032}
}
EUVIMED